Since 1991, three sequential prospective clinical trials have been conducted by the 'Head Start' (HS) Consortium in which young children with newly-diagnosed malignant central nervous system (CNS) tumors were treated with induction chemotherapy followed by single-cycle marrow-ablative chemotherapy and autologous hematopoietic rescue as a means of improving disease cure rate and quality of survival through avoidance (o 6 years old at diagnosis) or reduction (6-10 years old) of brain irradiation. Bone Marrow (HS I) or filgrastim-mobilized peripheral hematopoietic cells (HS II and III) were obtained following recovery from the first and/or second induction cycles. Radiotherapy was administered following all chemotherapy only for patients with residual tumor following completion of induction or with age greater than 6 years at diagnosis. Two hundred and twenty-six children were enrolled on three consecutive HS trials with primary malignant CNS tumors and underwent marrow-ablative chemotherapy. The 100-day treatment-related mortality (TRM) steadily declined as did grade IV transplant-related oropharyngeal mucositis. Factors most likely associated with the decrease in TRM and morbidity are increasing experience with the marrow-ablative chemotherapy regimen combined with improved leukapheresis and post-reinfusion supportive care techniques, contributing toward improved overall survival.
INTRODUCTION
In the 1980s to mid-1990s, treatment strategies for young children with primary malignant brain central nervous system (CNS) tumors utilized standard-dose chemotherapies to attempt to delay CNS irradiation until 3 or more years of age 1 or to avoid CNS irradiation entirely. [2] [3] [4] [5] Overall, 2-3 year PFS for children on these studies ranged from less than 10 to 34% for medulloblastoma, less than 30% for high-grade gliomas and 0-19% for other primitive neuro-ectodermal tumors. The median time to relapse was 6-9 months from diagnosis. Contemporaneously as well as subsequently, children with recurrent medulloblastoma, supratentorial primitive neuro-ectodermal tumor and high-grade gliomas were being treated with intensified chemotherapy including marrow-ablative chemotherapy and autologous hematopoietic cell rescue (AuHCR). [6] [7] [8] [9] [10] Furthermore, in young children relapsing after standard-dose chemotherapy regimens without irradiation, the French Society of Pediatric Oncology reported 50% EFS at a median of 31 months (n = 20) and with treatment-related mortality (TRM) at 5%. 11 Subsequently, with longer follow-up, the Memorial Sloan Kettering Cancer Center and the Children's Cancer Group (MSKCC/CCG-9883) reported in a similar cohort of young children 50% EFS at a median of 5 years and TRM at 10%. 12 These encouraging data in children with recurrent disease suggested that incorporation of marrow-ablative chemotherapy following a period of induction chemotherapy for newly-diagnosed young children with these malignant CNS tumors might produce substantially improved outcomes.
Since 1991, three sequential prospective multi-national clinical trials (including 39 participating institutions) were conducted by the 'Head Start' Consortium for young children with newly-diagnosed malignant CNS tumors. These trials sought to improve patients' cure rate and quality of survival through avoidance or reduction of CNS irradiation by utilizing a single cycle of marrow-ablative chemotherapy with autologous hematopoietic rescue as consolidation following initial induction chemotherapy. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] The goal of this present study was to examine changes in the rate of serious toxicities (grades III-V) associated with AuHCR in the first 100 days following transplant over the course of the 'Head Start' trials from 1991 to 2009.
PATIENTS AND METHODS
A retrospective chart review was performed using the patients from the 'Head Start' Consortium trials I-III who completed the entire course of treatment, including marrow-ablative chemotherapy and hematopoietic progenitor cell rescue. We did not include toxicities unrelated to treatment or those that had developed during treatment before transplantation.
Inclusion criteria and overall treatment design for 'Head Start' have remained unchanged throughout the three prospective trials, and have been previously reported. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] The basic treatment schema consisted of The single consolidation cycle consisted of carboplatin (20 mg/kg/ day or area under the curve of 7/day calculated by the Calvert formula, whichever was the lower dose) on days − 8 to − 6, followed by thiotepa (10 mg/kg/day) and etoposide (8.3 mg/kg/day) on days − 5 to − 3. In HS II and HS III, patients with high-grade gliomas received one of two different induction regimens, the first (Regimen B, HS II) consisting of three cycles of intensive procarbazine (10 mg/kg/day) on days 0-4, lomustine (3.5 mg/kg) on days 3 and 4, carboplatin (20 mg/kg/day) on days 3 and 4, and vincristine (0.05 mg/kg/day) on days 0, 7 and 14 or Regimen C, HS II and HS III, consisting of vincristine (0.05 mg/kg) on days 0, 7 and 14, carboplatin (20 mg/kg/day) on days 0 and 1 and oral temozolomide (6.5 mg/kg/day) on days 0-4. Figrastim (5 μg/kg/day) administered either subcutaneously or intravenously was the only hematopoietic growth factor utilized for patients on these trials; in particular, no patients received recombinant keratinocyte growth factor for mucositis prophylaxis in any HS trial. Bone marrow (HS I) or filgrastim-mobilized peripheral hematopoietic progenitor cells (HS II and HS III) were obtained following recovery from the first and/or second induction cycles. Radiotherapy was reserved following transplantation for patients with residual tumor assessed following completion of induction or for patients greater than 6 years old at diagnosis.
Statistical analyses
The 100-day mortality, infection and oropharyngeal mucositis rates were compared between the three 'Head Start' studies using a Fisher's Exact Test. Standard errors were also reported. P-values under 0.05 were considered as significant.
RESULTS

Patient characteristics
A total of 226 children were enrolled on three consecutive HS trials with primary malignant brain or spinal cord tumors and underwent marrow-ablative chemotherapy. 
Hematopoietic recovery
9 /L for 3 consecutive days without transfusion (Table 3) .
Toxicities
Toxicities considered in this study include grades III-V, as defined by National Cancer Institute criteria, in the first 100 days following transplant (days 0-100). Table 4 demonstrates a steadily declining toxic mortality rate from HS I (6.4 ± 3.57%) to HS II (2.1 ± 2.06%) to HS III (0.8 ± 0.76%). This decline is significant at the 5% level (P = 0.044). Table 5 is a complete list of grade III toxicities experienced by patients during HS III, from most to least common. Finally, Table 6 is a comparison of grade IV toxicities between HS I, II and III, demonstrating non-significant differences (P = 0.1015) in the 
DISCUSSION
Before the advent of marrow-ablative chemotherapy followed by AuHCR for the treatment of pediatric primary malignant CNS tumors in young children (traditionally considered less than 3 years of age at diagnosis), standard-dose chemotherapies were employed in an effort to reduce or eliminate irradiation exposure to the developing brain. [1] [2] [3] [4] [5] However, relapse was a significant issue and irradiation could not be avoided in most cases. Since the 'Head Start' trials began employing AuHCR with greater irradiation avoidance, we have documented improvements in quality of life by avoiding cranial irradiation, through prospectively conducted neuropsychological and quality of life follow-up studies. 23, 24 To assess the side effects of AuHCR in the setting of the treatment of young children with newly-diagnosed malignant CNS tumors, we present the analysis of serious toxicities (grades III-V) in the first 100 days following transplant. Our data show a marked decrease in the rates of TRM, grade IV oropharyngeal mucositis and grade IV infection sequentially over the course of the 'Head Start' trials.
Increasing experience with the marrow-ablative chemotherapy regimen, combined with improved leukapheresis and postreinfusion supportive care techniques, have likely contributed to the steady decline in transplant-related morbidity and mortality in this patient population, associated with improved overall survival. Factors that have not been considered in this analysis were the number of patients with positive versus negative spine magnetic resonance imaging before treatment, extent of surgical resection, status following induction therapy, hematopoietic progenitor cell source, induction regimen and tumor subtype. However, the diminishing size of individual sub-groups rendered statistical power to evaluate such factors not feasible.
The significance of these findings is that autologous hematopoietic progenitor cell rescue is a safe component of treatment for young patients with primary malignant CNS tumors, for whom even focal brain irradiation (or craniospinal irradiation) would be significantly and irreversibly detrimental to intellectual development.
The next 'Head Start' trial (HS IV) recently opened in 2015 with over 50 institutions conditionally committed to participate from several countries. Of note, the consolidation phase will consist of a randomization, for clinically and molecularly high-risk patients, between the single cycle marrow-ablative regimen used in prior 'Head Start' trials and the sequential three-cycle carboplatin and thiotepa regimen employed in the recently published CCG99703 trial. 25 The hypothesis underlying this randomization is that, for high-risk patients, the dose intensification implicit within the tandem regimen will result in improved EFS. Our over-arching goal continues to be to improve both overall irradiation-free survival and preserving intellectual and psychosocial functioning, for young children with newly-diagnosed malignant CNS tumors.
